Stem cell therapy in COVID-19: Pooled evidence from SARS-CoV-2, SARS-CoV, MERS-CoV and ARDS: A systematic review
Open Access
- 1 May 2021
- journal article
- review article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 137, 111300
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- IFITM-Family Proteins: The Cell's First Line of Antiviral DefenseAnnual Review of Virology, 2014
- Mesenchymal stromal cell injection protects against oxidative stress in Escherichia coli–induced acute lung injury in miceCytotherapy, 2014
- Intratracheal Administration of Umbilical Cord Blood-Derived Mesenchymal Stem Cells in a Patient with Acute Respiratory Distress SyndromeJournal of Korean Medical Science, 2014
- Comparison of the therapeutic effects of human and mouse adipose-derived stem cells in a murine model of lipopolysaccharide-induced acute lung injuryStem Cell Research & Therapy, 2013
- Bone Marrow Derived Mesenchymal Stem Cells Inhibit Inflammation and Preserve Vascular Endothelial Integrity in the Lungs after Hemorrhagic ShockPLOS ONE, 2011
- Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: Short-term and long-term outcomesHepatology, 2011
- Minimally cultured bone marrow mesenchymal stem cells ameliorate fibrotic lung injuryEuropean Respiratory Journal, 2009
- Introduction to Stem Cell TherapyJournal of Cardiovascular Nursing, 2009
- Therapeutic Effects of Bone Marrow-Derived Mesenchymal Stem Cells Engraftment on Bleomycin-Induced Lung Injury in RatsTransplantation Proceedings, 2008
- Immunopathogenesis of coronavirus infections: implications for SARSNature Reviews Immunology, 2005